A multimodality therapeutic application on Toxoplasma gondii encephalitis utilizing Spiramycin and ‘de novo’ Ferula asafetida in immunodeficient mice
Parasite Immunology · 2023
DOI: 10.1111/pim.13014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Parasite Immunology, 2023. Verfasst von Badria Hassan Almurshidi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Biology Department, United Arab Emirates University, Al Ain, UAE. Hauptthemen laut MEDLINE: Toxoplasma, Spiramycin, Ferula, Toxoplasmosis, Animal. Die Arbeit nennt 47 Literaturangaben. Gefördert von: A partial fund from United Arab Emirates University, United Arab Emirates University.
Abstract (Originalsprache)
This study investigated a ‘de Novo’ medicinal herb, Ferula asafetida (FA), against toxoplasma encephalitis either alone or combined with spiramycin (SP). Female Swiss‐Webster mice ( n = 72) were divided into three batches. Batch‐I received no DMS to serve as an immunocompetent control, batch‐II was immune‐suppressed with the DMS (0.25 mg/g/day) for 14 days pre‐infection, whilst batch‐III was immune‐suppressed with the DMS on the same day of infection. All experimental mice were inoculated with Toxoplasma gondii ME49 cysts ( n = 75). Each batch was split into four subgroups: Mono‐SP, mono‐FA, combined drug (SP + FA), or neither. Therapies were administered on day zero of infection in batches (I and II) and 35 days post‐infection in batch (III). Treatments lasted for 14 days, and mice were sacrificed 60 days post‐infection. Histopathological changes, cysts load, and CD4 and CD8 T‐cells were counted in brain tissues. The cyst‐load count in mice receiving SP + FA was significantly ( p < .0001) the least compared to the mono treatments in all protocols. Interestingly, the combined therapy demolished the T‐cell subsets to zero in immunocompetent and immunocompromised infected mice. In conclusion, F. asafetida might be a powerfully natural, safe vehicle of SP in the digestive system and/or across the brain–blood barrier to control toxoplasmosis even through immunodeficient conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biology Department, United Arab Emirates University, Al Ain, UAE.
- Immunology and Therapeutic Evaluation Department, Theodor Bilharz Research Institute, Giza, Egypt.
- Pathology Department, Theodor Bilharz Research Institute, Giza, Egypt.
- Biochemistry and Molecular Biology Department, Theodor Bilharz Research Institute, Giza, Egypt.
- Fatima College of Health Sciences, IAT, Abu Dhabi, UAE.
- Cancer Science Institute, National University of Singapore, Singapore, Singapore.
ORCID-Profile: Hend Okasha
Förderung
- A partial fund from United Arab Emirates University
- United Arab Emirates University
Zitieren
APA
Almurshidi, B. H., Fahmy, Z., El-Shennawy, A., Selim, E. A. H., Hammam, O. A., Okasha, H., Al-Hajj, W., Mahmoud, S. A., & Abuelenain, G. L. (2023). A multimodality therapeutic application on Toxoplasma gondii encephalitis utilizing Spiramycin and ‘de novo’ Ferula asafetida in immunodeficient mice. Parasite Immunology. https://doi.org/10.1111/pim.13014
Vancouver
Almurshidi BH, Fahmy Z, El-Shennawy A, Selim EAH, Hammam OA, Okasha H, et al. A multimodality therapeutic application on Toxoplasma gondii encephalitis utilizing Spiramycin and ‘de novo’ Ferula asafetida in immunodeficient mice. Parasite Immunology. 2023. doi:10.1111/pim.13014
BibTeX
@article{Almurshidi2023,
author = {Almurshidi, Badria Hassan and Fahmy, Zeinab and El-Shennawy, Amal and Selim, Eman A H and Hammam, Olfat Ali and Okasha, Hend and Al-Hajj, Wissam and Mahmoud, Salma Awad and Abuelenain, Gehan Labib},
title = {A multimodality therapeutic application on Toxoplasma gondii encephalitis utilizing Spiramycin and ‘de novo’ Ferula asafetida in immunodeficient mice},
journal = {Parasite Immunology},
year = {2023},
doi = {10.1111/pim.13014}
}
EUVIMED